Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Bowel Disorders: Introduction

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

Hepatic Drug Excretion: Enterohepatic Cycling

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Jaundice

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission.

The lancet. Gastroenterology & hepatology·2026

Same author

Eros and Thanatos of the new millennium: reflections on the relationship between a young man with Asperger's syndrome and an AI chatbot from the Italian forensic medical perspective.

La Clinica terapeutica·2026

Same author

Living with the Dead: Mad or Bad? Five paradigmatic cases of unprocessed grief.

La Clinica terapeutica·2026

Same author

Expectations and unmet needs for the post-COVID era reform of Italian primary care. Comparative perspectives across Europe and messages to the whole medicine community.

Internal and emergency medicine·2026

Same author

Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF).

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026

Same author

From desire to destruction: addiction, jealousy, and mental disorder in an Italian femicide case.

Forensic sciences research·2025

Search research articles

Related Experiment Videos

Long-term ursodeoxycholate improves circulating redox changes in primary biliary cirrhotic patients.

Ignazio Grattagliano¹, Vincenzo O Palmieri, Piero Portincasa

¹Clinica Medica A. Murri, Department of Internal Medicine and Public Medicine, University Medical School of Bari, Bari, Italy. i.grattagliano@semeiotica.uniba.it

Clinical Biochemistry

|October 4, 2011

Summary

Ursodeoxycholic acid (UDCA) effectively counteracts oxidative stress in early-stage primary biliary cirrhosis (PBC). However, its protective benefits diminish in advanced cholestasis.

Related Experiment Videos

Area of Science:

Hepatology
Biochemistry
Internal Medicine

Background:

Cholestasis is linked to systemic and hepatic oxidative and nitrosative stress.
Ursodeoxycholic acid (UDCA), a conjugated bile salt, may offer protection in cholestatic conditions.

Purpose of the Study:

To evaluate the efficacy of UDCA in mitigating oxidative and nitrosative stress markers in patients with primary biliary cirrhosis (PBC).

Main Methods:

Assessed circulating oxidative and nitrosative stress markers in PBC patients.
Measured markers before and during UDCA therapy (15-20mg/kg/day).

Main Results:

UDCA improved liver enzymes and normalized stress markers (thioredoxin, nitrotyrosine, nitrosothiols, K-18) in early-stage PBC (I-II).
Less significant improvements were observed in advanced PBC (III-IV), with higher stress marker levels.
Strong inverse correlations found between thioredoxin and nitrotyrosine/K-18 levels.

Conclusions:

UDCA effectively counteracts oxidative and nitrosative stress in PBC.
The therapeutic effect of UDCA is stage-dependent, being more pronounced in early disease.
Ongoing cholestasis limits the protective impact of UDCA.